Axogen develops and commercializes peripheral nerve regeneration and repair technologies for patients suffering traumatic nerve injuries or surgical complications that result in loss of motor or sensory function, organ dysfunction, or chronic pain. The company's core product portfolio includes Avance acellular nerve allografts, which bridge severed nerves without requiring immunosuppression; the Axoguard product line of porcine submucosa extracellular matrix devices for nerve protection and coaptation; and Avive+ Soft Tissue Matrix for tissue separation and protection. Axogen generates revenue primarily through U.S. hospital and surgery center distribution of these products to plastic reconstructive surgeons, orthopedic surgeons, and specialists in oral maxillofacial, head and neck, and urologic surgery, with approximately 65% of commercially insured U.S. patients now covered for Axogen product procedures.